Farther Finance Advisors LLC Acquires 315 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Farther Finance Advisors LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 17.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,146 shares of the medical equipment provider’s stock after acquiring an additional 315 shares during the quarter. Farther Finance Advisors LLC’s holdings in Intuitive Surgical were worth $936,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ISRG. Vanguard Group Inc. raised its holdings in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Intuitive Surgical by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after buying an additional 272,741 shares during the period. Capital World Investors boosted its holdings in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares in the last quarter. Edgewood Management LLC grew its stake in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after acquiring an additional 374,667 shares during the period. Finally, Jennison Associates LLC increased its holdings in shares of Intuitive Surgical by 4.6% during the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after acquiring an additional 198,483 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity

In related news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $411.00, for a total value of $575,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,655,048.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $411.00, for a total value of $575,400.00. The disclosure for this sale can be found here. Insiders have sold 53,056 shares of company stock valued at $25,276,044 in the last 90 days. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ISRG. Evercore ISI cut their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Barclays raised their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Finally, Truist Financial boosted their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Intuitive Surgical Stock Up 1.1 %

ISRG opened at $492.63 on Monday. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $493.97. The company’s 50-day moving average price is $454.69 and its two-hundred day moving average price is $414.94. The stock has a market cap of $175.06 billion, a price-to-earnings ratio of 88.92, a PEG ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the business earned $1.18 earnings per share. Intuitive Surgical’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.